Slide 1: Financial Results Quarter Ended June 30, 2015
Financial Results Quarter Ended June 30, 2015
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : Tuesday, August 11, 2015 Time : 5:00 pm IST Primary Number: +91 22 3938 1071 Secondary Number: +91 22 6746 8354 6000 1221 Available in – Ahmedabad, Bengaluru, Chennai, Cochin, Delhi, Gurgaon, Hyderabad, Kolkata, Noida. Accessible from all major carriers except BSNL/MTN
Slide 4: Q1'16 Results Analysis
JUBHANT LIFESCIENCES Q1’16 Results Analysis
Slide 5: Key Business Segments – Q1'FY16
Key Business Segments – Q1’FY16 Jubilant Life Sciences Pharmaceuticals Life Science Ingredients (51%) (49%) Generics Active Pharmaceutical Ingredients Advanced Intermediates Solid Dosage Formulations and Specialty Ingredients Specialty Pharmaceuticals (Sterile Products) Radiopharmaceutical
Slide 6: Income Statement – Q1'FY16
Income Statement – Q1’FY16 Particulars Q1'FY15 Q4'FY15 Q1'FY16 YoY Growth QoQ Growth (Rs Crs) (%) Total Income from Operations 1,473 1,537 1,459 -1% -5% Total Expenditure 1,328 1,289 1,129 Other Income 4 6 4 EBITDA including Other Income 150 253 333 123% 32% Depreciation 73 66 70 Finance Cost 63 80
Slide 7: Financial Highlights – Q1'FY16
Financial Highlights – Q1’FY16 • Income from Operations at Rs. 1,459 Crore • 23% YoY Growth in Pharmaceuticals segment revenues led by strong performance in APIs, Radiopharmaceuticals and CMO of Sterile Injectables • Specialty Ingredients and Nutritional Products drive performance in Life Science In
Slide 8: Segmental Revenue Analysis – Q1'FY16
Segmental Revenue Analysis – Q1’FY16 Revenue (Rs. Crs.) Revenue YoY Growth QoQ Growth Segmental Revenue Analysis Q1'FY15 Q4'FY15 Q1'FY16 Mix (%) % % Pharmaceuticals 604 763 741 51% 23% -3% Life Science Ingredients 869 774 718 49% -17% -7% Income from Operations 1,473 1,537 1,459 100% -1% -5% Inter D
Slide 9: Pharma Revenue – Geography wise – Q1'FY16
Pharma Revenue – Geography wise – Q1’FY16 Geo-wise Revenue (Rs crs) Q1'FY15 Q4'FY15 Q1'FY16 Mix % YoY % ROW India India 28 25 39 5% 41% 8.3% 5.3% Europe & International 576 738 702 95% 22% Japan USA & Canada 423 574 569 77% 35% 9.6% Europe & Japan 105 104 71 10% -32% USA & ROW (incl China) 49 60 61
Slide 10: Pharma Business Highlights – Q1'FY16
Pharma Business Highlights – Q1’FY 16 Generics Active Pharmaceutical Ingredients • Revenue growth backed by improvement in both pricing and volumes • Higher margins due to continuous cost reduction through processes and yield improvement • 39 commercial APIs, including 21 in North America, 24 in Eur
Slide 11: Pharma Business Highlights – Q1'FY16
Pharma Business Highlights – Q1’FY 16 Specialty Pharmaceuticals (Sterile Products) Radiopharmaceuticals • Sustained strong performance with significant improvement in margins • Strategic initiatives help improvement in business performance • Strong pipeline to sustain momentum going forward CMO of S
Slide 12: LSI Revenue – Geography wise – Q1'FY16
LSI Revenue – Geography wise – Q1’FY16 Geo-wise Revenue (Rs crs) Q1'FY15 Q4'FY15 Q1'FY16 Mix % YoY % ROW China India 402 401 363 51% -10% 9.3% 7.8% International 467 373 355 49% -24% USA & Canada 67 51 50 7% -26% India Europe & 50.6% Europe & Japan 222 179 183 25% -18% Japan 25.4% China 140 74 67 9%
Slide 13: LSI Business Highlights – Q1'FY16
LSI Business Highlights – Q1’FY 16 Advanced Intermediates, Specialty Ingredients and Nutritional Products • Price increase of 10% for Niacinamide taken during the quarter • Strong volumes and pricing witnessed in Fine Ingredients • Pyridine performance stable on quarter-on-quarter basis; pricing pre
Slide 14: Operating Expenditure Analysis – Q1'FY16
Operating Expenditure Analysis – Q1’FY16 % of % of % of YoY QoQ Expenses (Rs Crs) Q1 FY15 Q4 FY15 Q1 FY16 Sales Sales Sales Growth % Growth % Material Cost 719 49% 714 46% 546 37% -24% -24% Power & Fuel Cost 99 7% 95 6% 102 7% 3% 7% Employee Cost 272 18% 275 18% 274 19% 1% 0% Other Expenses 237 16%
Slide 15: EBITDA Analysis – Q1'FY16
EBITDA Analysis – Q1’FY16 EBITDA (Rs. Crs) Business Segments Q1'FY15 Q4'FY15 Q1'FY16 YoY Growth % QoQ Growth % Pharmaceuticals 36 200 225 532% 13% Life Science Ingredients 133 66 121 -9% 84% Less: Corp Expenses -19 -13 -13 Reported EBITDA 150 253 333 123% 32% Margins (%) YoY Variance (Bps) QoQ Varia
Slide 16: Debt Profile
Debt Profile Particulars 30-Jun-14 31-Mar-15 30-Jun-15 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Standalone 264 105 90 Swapped loan in Standalone 189 0 0 Subsidiaries 253 338 356 Total 706 443 445 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 160 1,513 1,466 Subsidiaries 50 509 485 Total 21
Slide 17: Outlook
Outlook In FY 2016, Pharmaceuticals segment to drive revenue growth with improvement in profitability across key businesses • Pharmaceuticals segment expected to drive growth on account of: • Growth in Radiopharmaceuticals • Normalization of CMO business • Growth in Generics through new products • L
Slide 18: For more information
For more information For Investors: Ravi Agrawal Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91-120-436 1002 Ph: +91-22-6645 1209 E-mail: ravi_agrawal@jubl.com E-mail: siddharth@cdr-india.com For Media: Sudhakar Safaya Saurabh Gupta Jubilant Life Sciences Limited Perfect Relati